Skip to main content

Table 1 Patients’ characteristics and outcomes

From: Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study

Characteristic All patients N = 2564 IPT group N = 1283 Control group N = 1281 P value
Sex: Females [Number (%)] 1949 (76.0) 994(77.4) 955(74.6) 0.083
Mean age in years (±SD) 38.6(10.3) 39.4(±10.5) 37.8(±10.1) <0.001
Median BMI (IQR) 22.8(7) 23.1(6) 22.7(6) <0.001
Patients on ARV drugs [Number (%)] 1913(75) 982(76.5) 931(72.7) 0.025
Median ARV duration in months(IQR) aN=1893 28.0(37) 31.0(38) 23(36) <0.001
Mean baseline CD4+ cells/μl (± SD), bN=2357 375 (±247) 415(±261) 330(±223) <0.001
Patients completing 6 months of IPT [N (%)] 1263(98) 1263(98) - NA
Patients developed TB during follow up [N (%)] 13 (1.1) 2 (0.2) 11 (0.9) 0.012
Number of deaths during follow up [N (%)] 27 (0.5) 3(0.2) 24(1.9) <0.001
Patients lost to follow up [N (%)] 146(5.7) 73(5.7) 73(5.7) 0.992
Patients transferred out [N (%)] 110(4.3) 31(2.4) 79(6.2) <0.001
Patients who withdrew consent [N (%)] 13(0.5) 10(0.8) 3(0.2) 0.052
Patients who completed study 2268(88.5) 1166 (90.9) 1102 (86.0) <0.001
  1. NA Not applicable
  2. aOnly 1893 were on ARV treatment
  3. bOnly 2357 patients had known baseline CD4 counts. Baseline here refers to the CD4 value at the time of study recruitment